Prospective study about the improvement of therapeutic invasiveness by oral intake of branched-chain amino acid (BCAA) supplement in hepatocellular carcinoma (HCC) patients after transcatheter arterial chemoembolization (TACE) and radiofrequency ablation (RFA)

Prospective study about the improvement of therapeutic invasiveness by oral intake of branched-chain amino acid (BCAA) supplement in hepatocellular carcinoma (HCC) patients after transcatheter arterial chemoembolization (TACE) and radiofrequency ablation (RFA) - Prospective study about the improvement of therapeutic invasiveness by oral intake of BCAA supplement in HCC patients after TACE and RFA

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000004624

Enrollment

150

Registered

2010-11-29

Start date

2011-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatocellular carcinoma

Interventions

Indirect calorimetry in pre-TACE and pre-RFA and 7 days after TACE and RFA on oral intake group of BCAA supplement Indirect calorimetry in pre-TACE and pre-RFA and 7 days after TACE and RFA on non-ora

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: All patients who were not adapted to the exclusion criteria were treated with segmental TACE and RFA.

Exclusion criteria

Exclusion criteria: Those who had refractory ascites, overt hepatic encephalopathy, uncontrolled esophageal varices, severe jaundice, Child's grade C and portal vein trunk thrombosis were excluded from the study. In addition, those who used intravenous albumin regularly were also excluded.

Design outcomes

Primary

Measure	Time frame
The improvement of the deterioration of liver metabolism (7 days after/ before TACE and RFA) and Child's score (3 months after/ before TACE and RFA) by oral intake of BCAA supplement.	—

Countries

Japan

Contacts

Public ContactMasaya Saito

Kobe University Graduate School of Medicine Department of Gastroenterology

masaya@med.kobe-u.ac.jp078-382-5111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026